UK markets closed

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
178.09+1.34 (+0.76%)
At close: 04:00PM EST
177.99 -0.10 (-0.06%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close176.75
Bid176.20 x 800
Ask179.00 x 800
Day's range177.01 - 178.90
52-week range130.96 - 178.92
Avg. volume5,459,190
Market cap314.591B
Beta (5Y monthly)0.54
PE ratio (TTM)65.47
EPS (TTM)2.72
Earnings date25 Apr 2024 - 29 Apr 2024
Forward dividend & yield6.20 (3.48%)
Ex-dividend date12 Apr 2024
1y target est165.58
  • Bloomberg

    Bond Markets Are Flooded With Deals to Fund M&A

    (Bloomberg) -- Demand has grown so fervent for corporate bonds that investors are once again willing to finance big mergers and acquisitions — something they hesitated to do for much of last year.Most Read from BloombergBuffett Says ‘Eye-Popping’ Results Unlikely With Record CashInvestors Flee Tumbling EV Upstarts Once Hailed as ‘Next Tesla’Bezos, Nvidia Join OpenAI in Funding Humanoid Robot StartupLitquidity Salary Reports Help Bankers Measure Up Annual RaisesBody of Alexey Navalny Is Given to

  • Zacks

    Pharma Stock Roundup: Pfizer's Velsipity Receives EU Nod, ABBV Gets New CEO & More

    European Commission approves Pfizer's (PFE) Velsipity ulcerative colitis (UC) pill. AbbVie (ABBV) appoints Robert A. Michael as the new CEO.

  • Bloomberg

    AbbVie Sells $15 Billion of Bonds to Buy ImmunoGen, Cerevel

    (Bloomberg) -- Pharmaceutical giant AbbVie Inc. sold $15 billion of bonds in the US investment-grade market on Thursday to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., adding to a recent rush of buyout financings. Most Read from BloombergNvidia Rises Most in About Nine Months as AI Drives SalesT-Bills Without Tax Bills? This Fund Says It Cracked the CodeStocks Rally as AI Craze Sweeps Across the World: Markets WrapAT&T Outage Triggered by Company Work on N